ConductScience.org, home

Comparison · NCT04475588-9c57485a

Arm A - Itolizumab + BSC vs Arm B - Best Supportive Care (BSC): Number and Percentage of Patients With Radiological Response

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm A - Itolizumab + BSC vs Arm B - Best Supportive Care (BSC): Number and Percentage of Patients With Radiological Response. Trial comparisons, record NCT04475588-9c57485a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04475588-9c57485a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.450.2580.658wilson
Risk in group 20.10.01790.404wilson
Risk difference, group 1 minus group 20.35-0.009580.574newcombe hybrid score
Risk ratio, group 1 over group 24.50.65930.7log
Odds ratio, group 1 over group 27.360.77969.6log
Number needed to treat, for one more participant with the outcome on Arm A - Itolizumab + BSC than on Arm B - Best Supportive Care (BSC)2.86from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm A - Itolizumab + BSC
Itolizumab IV infusion Itolizumab IV infusion: First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B Drug: Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
920OG000
Group 2Arm B - Best Supportive Care (BSC)Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc110OG001

Outcome

Type
SECONDARY
Title
Number and Percentage of Patients With Radiological Response
Description
Number of patients with improved X ray/CT findings as compared to baseline or returned to normal in the last assessment
Time frame
up to Day 30
Population

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Itolizumab in COVID-19 Complications
NCT number
NCT04475588
Phases
PHASE2
Conditions
Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19
Interventions
Itolizumab IV infusion, Best supportive care (BSC)
Lead sponsor
Biocon Limited
Results first posted
2021-05-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04475588-9c57485a